Drug intelligence / Profile preview

SirolimusEFR

Development stage: Unknown
Lead developer: Orchestra BioMed
Modality: Small Molecules
Administration: Local Delivery

Overview

SirolimusEFR is a proprietary extended-release formulation of sirolimus, developed by Orchestra BioMed. It is designed for local delivery via the Virtue Sirolimus AngioInfusion Balloon (SAB) device to prevent arterial restenosis, particularly in coronary in-stent restenosis (ISR). Sirolimus, also known as rapamycin, is a macrolide compound that acts as an immunosuppressant and antiproliferative agent by inhibiting the mammalian target of rapamycin (mTOR) pathway. This inhibition blocks cell-cycle progression, suppressing the proliferation of T cells and B cells, and reducing antibody production.

Targets

FKBP1AMechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on SirolimusEFR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SirolimusEFR.

Explore the full profile